Dachaigh › Leukemia Lymphocytic Cronach › Michigan

Sgrùdaidhean clionaigeach Leukemia Lymphocytic Cronach ann an Michigan

Tha 12 sgrùdaidhean airson Leukemia Lymphocytic Cronach a’ lorg phàirtichean aig làraichean ann an Michigan.

Bailtean ann an Michigan

Teacsa sgrùdaidh oifigeil (Beurla)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
agus 4 a bharrachd

A’ fastadhÌre 3

Aoisean 65 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
agus 68 a bharrachd

A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain

Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
agus 43 a bharrachd

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The Cancer and Hematology Centers, Grand Rapids

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Karmanos Cancer Institute, Detroit

A’ fastadhÌre 1/2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT05006716

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Corewell Health the Michigan Cancer Consortium, Grand Rapids

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Karmanos Cancer Institute, Detroit

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Karmanos Cancer Center, Detroit

A’ fastadhÌre 2

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07221500

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

A’ fastadhSgrùdadh amharc

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Cèit 2026 · NCT02269592

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Henry Ford Hospital /ID# 270973, Detroit

A’ fastadhÌre 3

Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Gibl 2026 · NCT06428019

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

A’ fastadhSgrùdadh amharc

Aoisean 12 gu 80 · Gach gnè · Air ùrachadh 28 Lùna 2025 · NCT07145411

Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.